P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES

• Caixia LI,
• Jia Wei,
• Liu Peng,
• He Huang,
• Fei LI,
• Yujun Dong,
• Qingqing Cai,
• Shenmiao Yang,
• Xinyou Zhang,
• Hui Zhou,
• Lu Zhang,
• Zaixing Shi,
• Zhiyu Liang,
• Binghao Wu,
• Keshu Zhou,
• Depei Wu

Affiliations

Caixia LI

1 The First Affiliated Hospital of Soochow University, Jiangsu, China

Jia Wei

2 Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, China

Liu Peng

3 Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai

He Huang

4 Zhejiang University – The First Affiliated Hospital, Hangzhou, China

Fei LI

5 The First Affiliated Hospital of Nanchang University, Nanchang, China

Yujun Dong

6 Department of Hematology, Peking University First Hospital Beijing, China

Qingqing Cai

7 Sun Yat-Sen University Cancer Center, Guangzhou, China

Shenmiao Yang

8 Peking University People’s Hospital, Beijing, China

Xinyou Zhang

9 Shenzhen People’s Hospital, Shenzhen, China

Hui Zhou

10 Hunan Cancer Hospital, Changsha, China

Lu Zhang

11 BeiGene (Shanghai) Co., Ltd., Shanghai, China

Zaixing Shi

11 BeiGene (Shanghai) Co., Ltd., Shanghai, China

Zhiyu Liang

11 BeiGene (Shanghai) Co., Ltd., Shanghai, China

Binghao Wu

11 BeiGene (Shanghai) Co., Ltd., Shanghai, China

Keshu Zhou

12 HeNan Cancer Hospital, Zhengzhou, China

Depei Wu

1 The First Affiliated Hospital of Soochow University, Jiangsu, China